Volume : 11, Issue : 08, August – 2024

Title:

A REVIEW OF THE EMERGING TREND IN BI-LAYER TABLET TECHNOLOGY

Authors :

Mr. Manishkumar Prajapati*, Mr. Abhijit Mohan Kanavaje, Mr. Shaikh Naumaan Naeem

Abstract :

The creation of controlled release formulations with a range of characteristics to guarantee efficient drug administration is ushered in by the bi-layer tablet. By physically separating APIs, bi-layer tablets can be an effective means of preventing chemical incompatibilities and producing distinct drug release patterns. A bi-layer tablet can be used to release two medications in combination in a sequential fashion or to release a single tablet continuously, with the first layer serving as the loading dosage and the second as the maintenance dose. The next piece addresses bi-layer tablet technology, difficulties in producing bi-layer tablets, different tablet presses that are employed, quality and GMP requirements for their manufacture, different bi-layer tableting methods, and current advancements in the field of bi-layer technology.
Key Words:- Bi-layer tablet, Incompatibility, multi-layer tablet, sustained release formulation.

Cite This Article:

Please cite this article in press Manishkumar Prajapati et al., A Review Of The Emerging Trend In Bi-Layer Tablet Technology., Indo Am. J. P. Sci, 2024; 11 (08).

Number of Downloads : 10

References:

1. Gopinath CV, Hima B, et.al. An overview on bilayer tablet technology. Journal of Global Trends in Pharmaceutical Sciences 2013; 4(2):1077-1085.
2. Swati A, navneet S, et.al. Bi-layer tablet technology – opening new ways in drug delivery systems: an overview. International Journal of Research in Pharmaceutical and Biomedical Sciences 2013; 4(1): 8-16.
3. Shweta P, Niraj M, et.al. Bilayer tablets: recent trends in oral drug delivery with present and prospects. International journal of universal pharmacy and bio sciences 2013; 2(3): 360-378.
4. Rishikesh G, Anwarul H, et.al. Bilayered tablet technology: an overview. World jounal of pharmaceutical research 2014; 3(4): 150-163.
5. Rahul M, Bhagwa P, et. al: A Review on immediate release drug delivery systems pharmatutor pharmacy infopedia 2014; 2(8): 95-109.
6. Abhijit RD, Priti DG, et.al. A review on: sustained release technology. International journal of research in ayurveda and pharmacy 2011;2(6): 1701-1708.
7. BijankG, Debnath R, et.al. Formulation development studies of bilayer tablet glipizide: a novel and evolutionary approach in the treatment of diabetes. Asian of Pharmaceutical and Clinical Research 2013; 6 4): 131-137
8. The United State Pharmacopeia- The National Formulary. 31st ed. Vol I, II, III. The Official Compendia of Standards. Asian edition 2008; 639-641
9. Larsson J. Methods for measurement of solubility and dissolution rate of sparingly soluble drugs 2010; 9- 12.
10. Rajesh S, Prateek C. Solubility enhancement by solid dispersion – a review. International journal of pharmaceutical & biological archives 2013; 4(4): 623 – 631.
11. Ketan TS, Anuradha KG, et.al. Drug solubility: importance and enhancement techniques. International Scholarly Research Network 2012; 1-10.
12. The Indian Pharmacopeia. Government of India, Ministry of Health and Family Welfare, 6thed. Vol I, II. Published by the Indian Pharmacopeia Commission, Ghaziabad 2010; 147, 185-198, 699,751-754
13. Anilkumar JS, Sachin SK, et.al. Comparative evaluation of formulations designed using chemically modified pectin and eudragit for sustained release of nateglinide. International journal of novel drug delivery technology 2012; 2(1): 240-248.
14. Ravindra L, Bhanudas S,Curcumin-ZN-Ropinirole hydrochloride combination therapy for Plasmodium Berghei Infected Mice. International Journal of pharmacy and pharmaceutical sciences 2015; 7(9): 41-45.
15. Qui Y. Rational Design of Oral Modified-release Drug Delivery Systems. In: Qui Y, Chen Y, Zhang GGZ,editors. 1sted. Development of solid oral dosage form pharmaceutical theory and practice. Academic pressElsevier inc. 2009; 469-485.
16. Satinder K, Shashi K, et.al. Sustained release drug delivery system: a review. International Journal ofInstitutional Pharmacy and Life Sciences 2012; 2(3): 356-376
17. Zameeruddin M, Namdev H, et.al. Recent advances of sustained release oral drug delivery system: a review. World journal of pharmacy and pharmaceutical sciences 2014; 3(5): 1477-1490.
18. Libermann H, Lachman L and Schwartz J. Pharmaceutical Dosage forms: Tablets. 2ndEd. Marcel Dekker, New York 1990; 1:131.
19. Vikas D, Asha K. Role of biopharmaceutical classification system in drug development program. Journal of current pharmaceutical research 2015; 5(1): 28-31.
20. Songa AS, Meka VS, et.al. Design and evaluation of lornoxicam bilayered tablets for biphasic release. Brazilian Journal of Pharmaceutical Sciences 2012; 48(4): 610-619.
21. Guido S, David j, et.al. Influence of Piperine on the Pharmcokinetic of curcumin in animals and human volunteers. Planta Medica 64 1998; 353-356
22. Qui Y. Rational Design of Oral Modified-release Drug Delivery Systems. In: Qui Y, Chen Y, Zhang GGZ,editors. 1sted. Development of solid oral dosage form pharmaceutical theory and practice. Academic pressElsevier inc. 2009; 469-485.
23. ICH Harmonized Tripartite Guideline, International Conference on Harmonization, Stability testing of new drug substances and products Q1A (R2) and Evaluation for stability data Q1E.
24. The Merck Index, An Encyclopedia of chemicals, 14th ed., Merck research laboratories division of Merck and co.INC: 2006, 6428.
25. Martindale, The complete Drug Reference, 35thed. Pharmaceutical Press, London, Chicago, 1, 2007,413.
26. Remington, The science and practice of pharmacy, 21st ed., A Wolters Kluwer business, 2, 2007, 1455.
27. AHFS (American Society of Health-system Pharmacists) Drug information, published by American society of health- system pharmacists, 2012, 3220-21.
28. The Indian Pharmacopeia. 6thed.Vol I, II. Government of India, Ministry of Health and Family Welfare, published by the Indian Pharmacopeia Commission, Ghaziabad. 2010; p.147, 185-198.
29. Bindu v, Nischala M, et.al, An Overview on Bilayer Tablet Technology, Journal of Global Trends in pharmaceutical sciences, 4(2), 2013, 1085-97.
30. Gupta B, Debnath R, Ghosh S, et.al, Formulation Development Studies of Bilayer Tablet Glipizide: A Novel and Evolutionary Approach in the Treatment of Diabetes, Asian Journal of Pharmaceutical and Clinical Research, 6(4), 2013, 131-37.
31. Aggarwali S, syan N, Mathur P, Bi-Layer Tablet Technology- Opening New Ways in Drug Delivery System: An Overview, International Journal of Research in Pharmaceutical and Biomedical Sciences, 4(1), Jan-Mar 2013, 8-16.
32. Gupta B, Bebnath R, et.al, Formulation development studies of bilayer tablet Glipizide: A novel & evolutionary approach in the treatment of diabetes, Asian journal of pharmaceutical and clinical research, 6(4),2013, 131-137.
33. Anilkumar S, Sachin K, et.al, Comparative evaluation of formulation design using chemically modified pectin and eudragit for sustain release nateglinide, International journal of novel drug delivery technology, 2(1), 2012, 240-247.
34. Sunil S, Srikant M, et.al, Design and evaluation of lornoxicam bilayer tablets for biphasic release, Brazilian journal of pharmaceutical science, 48,2012, 609-619.
35. Preeti K, Kasture P, International journal of pharmatech research, 3(4), 2011, 1919-1929. Martindale, The Extra Pharmacopoeia, 31sted. The Pharmaceutical Press, London; 1996. p.936–937.
36. Martin A, Bustamante P and Chun A. Micromeritics. Physical Pharmacy Physical Chemical Principles in the Pharmaceutical Sciences, 4th ed., Lippincott Williams and Wilkins, Baltimore; 2002. p. 446–448.
37. Bogan RK. Treatment options for insomnia. Pharmacodynamics of zolpidem extended release to benefit next-day performance. Postgraduate Medicine 2008; 120: 161–171.
38. Kulkarni A, Bhatia M. Development and evaluation of bilayer floating tablets of atenolol and lovastatin for biphasic release profile. Iranian Journal of Pharmaceutical Research 2009; 8: 15–25.
39. Nirmal J, Saisivam S, Peddanna C, Muralidharan S, Nagarajan M et al. Bilayer tablets of atorvastatin calcium and nicotinic acid: formulation and evaluation. Chem. Pharm. Bull. 2008; 56: 1455–1458.
40. safety and efficacy of extended-release guaifenesin/pseudoephedrine hydrochloride for symptom relief as an adjunctive therapy to antibiotic treatment of acute respiratory infections. Postgraduate Medicine 2008; 120: 53–59.
41. Maggi L, Segale L, Conti S, Ochoa Machiste E, Conte U. Preparation and evaluation of release characteristics of 3TabGum, a novel chewing device. Eur. J. Pharm. Sci. 2005;4: 487–493.
42. Park CR. Munday D.L. Development and evaluation of a biphasic buccal adhesive tablet for nicotine replacement therapy. International Journal of Pharmaceutics 2002; 237: 215–226.
43. Sungthongjeen S, Sriamornsak P, Puttipipatkhachorn S. Design and evaluation of floating multi-layer coated tablets based on gas formation. Eur. J. Pharm. Biopharm. 2008; 69: 255–263.
44. Muzzio FJ, Lerapetritou M, Portillo P, Llusa M, Levin M, Morris KR, Soh LPJ, McCann RJ, Alexander A. A forward looking approach to process scale-up for solid dose manufacturing. In: Augsburger, L.L., Hoag, S.W. (Eds.), Pharmaceutical Dosage Forms: Tablets, Volume 3: Manufacture and Process Control; 2008.
45. Yang L, Venkatesh G, Fassihi R. Compaction simulator study of a novel triple-layer tablet matrix for industrial tableting. International Journal of Pharmaceutics 1997; 152: 45–52.
46. LaForce C, Gentile DA, Skoner DP. A randomized, double blind, parallel group, multicenter, placebo-controlled study of the
47. Abshagen U, Spo ̈rl-Radun S. First data on the effects and pharmacokinetics of isosorbide-5- mononitrate in normal man, Eur. J. Clin. Pharmacol. 1981;19:423–429.
48. Hutt V, Bonn R, Fritschi E, Jaeger H. Evaluation of the pharmacokinetics and absolute bioavailability of three isosorbide- 5- mononitrate preparation in healthy volunteers,
49. Schaumann W. Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate, Int. J. Clin. Pharmacol. Ther. Toxicol. 1989;27:445–
50. International Journal of Pharmaceutical Research & Development ISSN: 0974 – 9446Arzneim. – Forsch. Drug Research 1995; 19:142–145.
51. Reiniger G, Blasini R, Bru ̈gmann U, Rudolph W.Toleranzentwicklung hinsichtlich der anti ischamischen Wirkung von Isosorbid dinitratbei regelmassiger, mehrfach taglicher Verabreichung, Herz. 1984; 9: 146–152.
52. Herrmann H, Kuhl A, Maier-Lenz H. Influence of the time of dosage of isosorbide mononitrate on objective and subjective angina pectoris parameters, Arzeim.- Forsch. Drug Research 1988; 38: 694–698.
53. Raparla DV and Murthy TE. Formulation and evaluation of oral controlled release Glimepiride matrix tablets. Advances in Phamacology and Toxicology 2007; 8: 59-62.
54. Benham PP, Crawford RJ, Armstrong CG. Mechanics of Engineering Materials, 2nd ed. Longmans, Harlow, UK, 1999; 139–144.
55. Shirwalkar AA, Kumar SM, Jacob S. Recent developments in floating drug delivery systems for gastric retention of drugs, an overview. Indian drugs. 2006; 43(9): 697-704.
56. Bourne DW. Pharmacokinetics. G. S. Banker and C. T. Rhodes Modern Pharmaceutics, 4th ed., Marcel Dekker, New York; 2002. p.67–92.
57. Lechman L, Liberman HA, Kanig JL. The Theory and Practice of Pharmacy, 3rd Ed., Varghese Publishing House, Bombay;1987. p.430-453.
58. 25. Robinson JR, Lee VH. Controlled Drug Delivery: Fundamentals and Applications 2nd Ed., Marcel Dekker,New York; 1987. p.4-36.
59. 26. The United States Pharmacopoeia, United states Pharmacopoeial convention, Inc., Rockville, MD, 2000:1944.
60. 27. Singh BN, Kim KH. Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention, Journal of Control Release 2000; 63: 235-59.